Cystic Fibrosis Foundation issued the following clinical trial alerts in November.
November 19, 2021
Study to evaluate Creon in adults with cystic fibrosis or chronic pancreatitis
Status: Enrolling
Description: This study will look at the symptoms of exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis or chronic pancreatitis treated with Creon with an alternate source of active drug. Creon is a drug approved to treat EPI.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 3
Length of Participation: 142 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05069597
November 30, 2021
Status: Enrolling
Description: This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.
Age: 2 Years to 5 Years
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: No FEV1 Limit
Number of Visits: 9
Length of Participation: 32 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04537793